Clinical Trials – The Importance of Diversity in Clinical Trials

Clinical trials help us assess the safety and effectiveness of upcoming or existing therapeutics. The clinical trials turn out to be even more successful if the trial participants are representatives of the wider disease population. Lack of diversity in the clinical trial population often minimizes the quality of data obtained for drug safety and efficacy profiles. Furthermore, conducting clinical trials with a diverse demographic set-up ensures a better understanding and a more targeted approach to the administration of therapeutics while providing access to novel groundbreaking therapies in clinical trials.

This diversity in clinical trials market research report provides an analysis of clinical trial racial representation data and evaluates racial demographics across a number of clinical trial sectors to highlight the level of diversity.

Diversity in Clinical Trials – Barriers and Improvement Strategies

For diversity in trials to be improved, factors negatively influencing diversity must be recognized. A major barrier in effectively studying diversity in clinical trials is the low levels of race disclosure of study participants. Increased disclosure would allow for a more accurate assessment of race disparities in the clinical trial landscape.

Strategies to improve diversity across the Pharma industry must be considered where trial populations vastly differ from the disease demographics. Sponsors involved in trials should outline specific targets prior to enrolment to ensure the study population is representative of the disease populations. These targets should be communicated with investigators and primary healthcare providers to reduce the level of implicit bias during recruitment.

For more understanding of strategies to overcome challenges to diversity in clinical trials, download a free sample

Diversity in Clinical Trials Market by Region

The key regions in the clinical trials market are North America, South and Central America, Europe, Middle East and Africa, and Asia-Pacific, among others. North America and South and Central America lead the reporting of race data followed by Europe, Middle East and Africa, and Asia-Pacific, respectively as of July 2022.

Clinical Trials with Disclosed Racial Representation Data, by Region

For more insights on diversity in clinical trials by region, download the free sample

Diversity in Clinical Trials Market by Country

The key countries in the clinical trials market with disclosed racial representation data are Canada, the US, Spain, Germany, France, the UK, Japan, China, India, and Iran among others. Canada had the highest percentage of clinical trials with disclosed racial representation data, followed by the US, Spain, and Germany.

Clinical Trials with Disclosed Racial Representation Data, by Country

For more insights on the diversity in clinical trials by country, download the free sample

Diversity in Clinical Trials Market by Demography

The key demographic groups or study subjects in the clinical trials reporting race data are White, Black or African Americans, Asians, American Indian or Alaska Native, Mixed, and Native Hawaiian or Pacific Islander or Indigenous Australians. Globally, in clinical trials reporting race data, the overwhelming majority of study subjects are white.

Clinical Trials with Disclosed Racial Representation Data, by Demography

For more insights on the diversity in clinical trials by demography, download the free sample

Diversity in Clinical Trials Market by Sponsor Type

The key sponsor types in the clinical trials market are industry sponsors and institutional sponsors. Industry-sponsored trials have a greater proportion of white participants than institutional trials.

Clinical Trials with Disclosed Racial Representation Data, by Sponsor Type

For more information on sponsor types in the clinical trials market, download sample report

Diversity in Clinical Trials Market by Therapy Areas

The key therapy areas in the clinical trials market are Oncology, Central Nervous System Disorders, Infectious Diseases, Cardiovascular, and Metabolic Disorders. Of the top therapy areas, Oncology has the highest representation of Asian participants, with white participants forming the overall majority.

Clinical Trials with Disclosed Racial Representation Data, by Therapy Areas

For more information on therapy types in the clinical trials market, download sample report

Diversity in Clinical Trials Market by Company

Some of the leading companies in the clinical trials market are Novartis, GSK, Pfizer, Johnson & Johnson, AstraZeneca, Eli Lily, F.Hoffmann-La Roche, Merck & Co, AbbVie, and Bayer among others. GSK showcases the most well- rounded diversity where the top three common racial groups are concerned.

Clinical Trials with Disclosed Racial Representation Data, by Company

For more information on diversity in companies in the clinical trials market, download the sample report

Diversity in Clinical Trials Market Overview

Scope

The clinical trials data used for these analyses was extracted from GlobalData’s Clinical Trials Database, captured on June 16 and July 19, 2022. The data primarily includes clinical trials initiated from January 1, 2013 to June 16, 2022. Disclosed racial representation data has been analyzed by location, by year, phase, therapy area, sponsor type, top industry sponsors, pivotal study status, single country and multinational trials, decentralized trials, and CRO involvement. Additional analysis on obstacles in the recruitment of diverse subject populations in clinical trials and steps which can be taken to increase diversity have also been included.

Reasons to Buy

• Provides a breakdown of racial representation data across a number of clinical trial sectors.
• Identifies which areas are lacking in clinical trial population diversity.
• Highlights the variation in diversity in the industry and against institutional sponsors.
• Documents the barriers to diversity in clinical trials and outlines steps to improve it.
• Assesses how decentralized and virtual components in clinical trials affect diversity.